Breathe
again

Presenting BES-1001

Effective drug-free and non-invasive treatment of nasal congestion and pain
with a handheld, connected medical device

Coming Soon!

1 in 5 people

in the world suffer from chronic nasal congestion

Constant discomfort, pain and difficulty sleeping significantly affect patients’ quality of life


Side effects, limited efficacy and inconvenience are key limitations of available treatments


As a result of suboptimal treatments available, the societal burden of chronic nasal congestion can exceed $10.000 /patient /year

 

Orlandi et al., International Consensus Statement on Allergy and Rhinology: Rhinosinusitis Executive Summary (2016) 

Wise et al., International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2020)

BES-1001

is a medical device that treats nasal congestion and facial pain using Precisely Modulated Acoustic Energy (PMAE)

  • Drug-free         Device can be used as a monotherapy or in                              combination with medications
  • Non-invasive    Treatment is comfortable and convenient,                                lasting 1 minute/side of the face
  • Handheld          Easy-to-use, pocket-sized and connected,                               BES-1001 can be used anywhere

BES-1001

is a medical device that treats nasal congestion and facial pain using Precisely Modulated Acoustic Energy (PMAE)

  • Drug-free Device can be used as a monotherapy or in combination with medications
  • Non-invasive Easy-to-use, pocket-sized and connected, BES-1001 can be used anywhere
  • Handheld Easy-to-use, pocket-sized and connected, BES-1001 can be used anywhere

Human studies

showed BES-1001’s patent- protected frequency range promotes clearance of nasal congestion
  1. Proof-of-concept resonance validation study; 2. Cold air challenge; 3. Saccharine test.

Patients eligible

for treatment include populations with highly prevalent ENT disorders

CRS: Chronic rhinosinusitis;

Figures refer to EU4, UK, US and Japan;

Differentiated

from devices approved to treat nasal congestion or facial pain

Device ready

for clinical development and IP protected

Tech platform

based on acoustic wave therapy and IP presents major upsides

*Figures refer to EU4, UK, US and Japan

Networked

swiss

and lean operating model combining internal experience in the life sciences with external experience of international service providers

Konstantinos Efthymiopoulos

PharmD, PhD, MBA

Chairman & Managing Director

Current key partners